What move does the options market price into Revolution Medicines's report?

Implied ±22.5%, either direction · provisional.

RVMDNasdaqBiological Products, (No Diagnostic Substances)

Revolution Medicines, Inc. (RVMD) earnings date, market-implied expected move, and options open interest by expiry

199.24

+5.01 · +2.58%

post 220.50 +10.67%

After hours16:45 ETdelayed

Open191.26Volume1.4MMkt cap$41.6BEPS-8.86

Day191.26 – 220.00100%52-wk57.74 – 224.3198%

RVMD

Revolution Medicines, Inc.

OpenVolumeMkt capP/EEPSDiv yield

Day – 52-wk –

Expected move

Inputs

±22.5%implied · straddle

156.20246.90

spot 201.55exp Mar 19ATM strike 200ATM straddle 53.35IV 49%

Nov 4 closeprovisional

Expected move

Inputs

News

Next report

Last report

Nov 4

after close

confirmedNov 3 close

Implied vs realized

Linked news

7hRPRX · customerRoyalty Pharma posts Q3 net income $266,637 thousand; nine-month net $816,379 thousand
5dSNY · customerSanofi Q3 sales €14,444 million, business EPS €3.55; upgrades 2026 guidance

News

Largest filed tie

13F top-10 QoQ

+23.58%

shares held · 10 largest managers

13F · Jun 30 '26127d lag

700 managers

Top fund weight

1.20%

RVMD weight · XBI

N-PORTJun 30 '26

3 funds

Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied

Revolution Medicines (RVMD) is expected to report on Feb 24 after close (estimated date).

Implied vs realized

1 report

—≥ implied

Q2 FY26Aug 5 '26confirmed±7.9%▲+0.26%×0.03

quarterimplied−10%0+10%realized×

Q2 FY26±7.9%▲+0.26%×0.03

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Implied vs realized

Positioning

OI · 4 expiries · Nov 3 close

0.69OI · 4 expiries · Nov 3 closeP/C open interest · Mar 19 · first expiry after the report

PUTS · chgexpiry · days · P/CCALLS · chgP/C

3,825+5%Nov 2016d1.033,713+1%1.03

6,7250%Dec 1844d1.454,6530%1.45

4,004−2%Jan 1572d0.3511,3900%0.35

report · Feb 24 · after close · est.

663+1%Mar 19135d9660%

ExpiryPutsCallsP/C

Nov 2016d3,825+5%3,713+1%1.03

Dec 1844d6,7250%4,6530%1.45

Jan 1572d4,004−2%11,3900%0.35

report · Feb 24 · after close · est.

Hatched = puts · solid = calls · bars scaled per expiry · chg = OI vs prior sessionSource: options EOD

Positioning

Linked exposure

scenario · straddle±22.5%

Funds 3

XBI±0.3%

VTI±0.0%

VT±0.0%

Dashed = straddleMethod Source: SEC filings · N-PORT · market data

Linked exposure

Revenue flow

Q4 FY23 · derived from FY

−21770.49%Q4 FY23 · derived from FYnet margin

Revenue$742,000—

Gross profit$742,000100.00%—

Operating income−$180M−24256.47%−46.03%

Pre-tax income−$161M−43.54%

Net income−$162M−21770.49%−48.97%

Operating expenses$181M+46.64%

Tax$343,000+108.87%

Other income$19M+71.64%

Derived: FY − Q1–Q3 · QE Dec 31 '23 · bars = % of revenue

Revenue flow

Intraday

15m bars

Long dash = implied range · Nov 4 close · Hatch = extended hours · ▯ up · ▮ downSource: market data · 16:45 ET

Intraday

Event sensitivity

NFP ×1.15· ±2.6% vs ±2.2% · 10 releases

eventrelease day|move|up · n×base

NFPjobs report±2.6%5 of 10×1.15

PPIproducer prices±2.2%4 of 10×0.97

GDPgross domestic product±2.1%12 of 19×0.93

PCEpersonal income & outlays±1.9%12 of 19×0.83

FOMCrate decision±1.8%13 of 24×0.80

CPROFcorporate profits±1.7%8 of 12×0.76

CPIconsumer prices±1.1%6 of 10×0.49

Bar = avg |move| to ±3% · tick = ±2.2% avg day · ×base = |move| ÷ ±2.2% · min 6 releases

Earnings history

EPS -3.06 · consensus —

Quarter	Reported	EPS	Consensus
Q2 FY26	Aug 5 '26 · confirmed	-3.06	—
Q1 FY26	—	-2.29	—

Source: filed financials

Methodology

ties · implied moves · holdersMethod